Stem cell weekly reads: Jamie Thomson, Lamin B1, CRISPR

The big news of the week was a $3.6 million settlement by a stem cell clinic, StemGenex, and one of its doctors in a class-action suit.

I covered this StemGenex settlement and so did Michael Hiltzik of the LA Times and Paul Schloesser at Endpoints. I’d say this was good news for the stem cell field and patients.

Also, the Niche has some good news too as our stem cell YouTube channel continues to do well and we’re above 400 subscribers so please subscribe to help us spread the word.

Stem cell pioneer James Thomson announced his retirement.

Recommended reads

Lamin B1 deletion in myeloid neoplasms causes nuclear anomaly and altered hematopoietic stem cell function, Cell Stem Cell.

DNA replication fork speed underlies cell fate changes and promotes reprogramming, Nature.

AC010973.2 promotes cell proliferation and is one of six stemness-related genes that predict overall survival of renal clear cell carcinoma, Scientific Reports.

Jamie Thomson, who first characterized human embryonic stem cells, has announced his retirement.

An extinct rat shows CRISPR’s limits for resurrecting species, ScienceNews. Here’s the original research paper: Probing the genomic limits of de-extinction in the Christmas Island RatCurrent Biology.

It’ll be important to learn the cause of his death and if his immune system rejected the pig heart.

Leave a Reply